fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

VISTA ALERT: INVO Bioscience (NASDAQ: INVO) Releasing Results After Market Close Today! – Conference Call 4:30pm ET

By John F. Heerdink, Jr.

INVO Bioscience, Inc.(NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its fourth quarter and fiscal year 2020, ended December 31, 2020, after the market close on Tuesday, March 30, 2021. The Company has scheduled a conference call that same day, Tuesday, March 30, 2021, at 4:30 pm ET, to review the results.

Fourth Quarter and Fiscal Year 2020 Conference Call Details

Date and Time: Tuesday, March 30, 2021 at 4:30 pm ET

Call-in Information: Interested parties can access the conference call by dialing 877-270-2148 or 412-902-6510.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/ or https://www.webcaster4.com/Webcast/Page/2162/40436.

Replay: A teleconference replay of the call will be available through April 6, 2021 at 877-344-7529 or 412-317-0088, confirmation #10153332. A webcast replay will be available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/ for 90 days.



On Monday, March 15, INVO announced the signing of a 50/50 joint venture agreement in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD, to open the first Joint Venture INVO-exclusive clinic in the United States. The INVO clinic will be located in Birmingham, Alabama and is expected to be operational in the second half of 2021. Together, the team of Cataldo, Hammond, and Ray has been one of the IVF industry’s leading advocates of the INVOcell solution. Since 2018, they have performed more than 700 cycles with INVOcell with patients traveling to Birmingham from more than 28 states across the country to access the procedure. Dr. Hammond and Lisa Ray are also members of the INVO Bioscience Scientific Advisory Board.


Steve Shum, CEO of INVO Bioscience (NASDAQ: INVO)

“This is an important milestone for INVO Bioscience as we plan the opening of the first Joint Venture INVOcell-exclusive clinic in the United States in partnership with leading reproductive specialists. The exclusive clinic model creates a unique opportunity for INVO and our partners to drive accelerated adoption of the INVOcell solution while increasing the capacity of the infertility industry, improving affordability, and facilitating greater access for patients. We are fortunate to partner with such high caliber partners as Drs. Cataldo, Hammond and Ray, who are extremely well-versed in the INVOcell technology and have a proven track record of successful implementation within a thriving clinical setting. We believe their expertise will be invaluable as we build a successful operating model which can be replicated for additional INVOcell-exclusive clinics.  We look forward to reporting on those additional activities in the near future,” Steve Shum, CEO of INVO Bioscience (NASDAQ: INVO)
Post View Count : 1223


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us